Levoverbenone

Levoverbenone

SCHEMBL21046

CC1=CC(=O)[C@H]2C[C@@H]1C2(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
BUB1 O43683 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Verbenone SCHEMBL12914978 1.00 TSHR (0.41) TSHRMAPK1BUB1
Verbenone SCHEMBL3506768 1.00 TSHR (0.41) TSHRMAPK1BUB1
Verbenone SCHEMBL6562635 1.00 TSHR (0.41) TSHRMAPK1BUB1
Verbenone SCHEMBL10615025 1.00 TSHR (0.41) TSHRMAPK1BUB1
Verbenone SCHEMBL118161 1.00 TSHR (0.41) TSHRMAPK1BUB1
Verbenone SCHEMBL17204705 0.91 TSHR (0.35) TSHRMAPK1BUB1
Verbenone SCHEMBL11546159 0.83 TSHR (0.31) TSHRMAPK1
Eucalyptol SCHEMBL647135 0.80 TSHR (0.50) TSHRMAPK1
SCHEMBL11762192 0.74 BUB1 (0.31) BUB1
SCHEMBL18944189 0.72 BUB1 (0.33) BUB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651713-A1 PLANT TREATMENT COMPOSITIONS COMPRISING CHITOSAN-COATED EMULSIONS Universität Münster (DE) 2025-11-26 EP claimed
US-20250255781-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-08-14 US claimed
US-12296043-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2025-05-13 US claimed
CN-119823825-A Myrtle essential oil and application of compound essential oil based on myrtle essential oil in pest control 广东海洋大学 2025-04-15 CN claimed
EP-4510999-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS Bristol-Myers Squibb Company (US) 2025-02-26 EP claimed
WO-2024153800-A1 PLANT TREATMENT COMPOSITIONS COMPRISING CHITOSAN-COATED EMULSIONS UNIVERSITÄT MÜNSTER (DE) 2024-07-25 WO claimed
US-20240165020-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-05-23 US claimed
EP-4360653-A2 LIQUISOFT CAPSULES Patheon Softgels Inc. (US) 2024-05-01 EP claimed
US-11938242-B2 Apparatus and method for reducing malodor on surfaces THE PROCTER & GAMBLE PLAZA (US) 2024-03-26 US claimed
US-11872307-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2024-01-16 US claimed
EP-2729136-A1 DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION Biocopea Limited (GB) 2014-05-14 EP claimed
EP-2608847-A1 THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY Biocopea Limited (GB) 2013-07-03 EP claimed
WO-2013004999-A1 DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION BIOCOPEA LIMITED (GB) 2013-01-10 WO claimed
WO-2012025761-A1 THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY BIOCOPEA LIMITED (GB) 2012-03-01 WO claimed
US-20100087455-A1 SUBSTITUTED XANTHINE COMPOUNDS AUSPEX PHARMACEUTICALS, INC. (US) 2010-04-08 US claimed
EP-2170825-A2 SUBSTITUTED INDOLES Auspex Pharmaceuticals, Inc. (US) 2010-04-07 EP claimed
US-20090203763-A1 SUBSTITUTED BENZHYDRYLETHERS AUSPEX PHARMACEUTICALS, INC. (US) 2009-08-13 US claimed
WO-2009094457-A2 SUBSTITUTED BENZHYDRYLETHERS AUSPEX PHARMACEUTICALS (US) 2009-07-30 WO claimed
US-20090191183-A1 SUBSTITUTED INDOLES AUSPEX PHARMACEUTICALS, INC. (US) 2009-07-30 US claimed
WO-2009018280-A2 SUBSTITUTED INDOLES AUSPEX PHARAMACEUTICALS, INC. (US) 2009-02-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11938242-B2 Apparatus and method for reducing malodor on surfaces AOX1, AOC2, AOC1 TSHR 2457/4885MAPK1 3739/4885BUB1 1656/4885
US-20100087455-A1 SUBSTITUTED XANTHINE COMPOUNDS XDH, HPRT1, SLC10A1 TSHR 3552/4885MAPK1 3541/4885BUB1 4652/4885
US-20090203763-A1 SUBSTITUTED BENZHYDRYLETHERS UGT2B7, CYP3A7, CYP3A43 TSHR 3854/4885MAPK1 4587/4885BUB1 1832/4885
US-20090191183-A1 SUBSTITUTED INDOLES CYSLTR1, LTB4R, LTB4R2 TSHR 606/4885MAPK1 3769/4885BUB1 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.